請用此 Handle URI 來引用此文件：
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/69895完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 翁啟惠(Chi-Huey Wong) | |
| dc.contributor.author | Li-Ju Huang | en |
| dc.contributor.author | 黃麗如 | zh_TW |
| dc.date.accessioned | 2021-06-17T03:32:54Z | - |
| dc.date.available | 2019-03-02 | |
| dc.date.copyright | 2018-03-02 | |
| dc.date.issued | 2018 | |
| dc.date.submitted | 2018-02-12 | |
| dc.identifier.citation | 1. Varki, A. Glycobiology 2017, 27, 3.
2. Varki, A.; Lowe, J. B., Biological roles of glycans. 2009. 3. Defaus, S.; Gupta, P.; Andreu, D.; Gutierrez-Gallego, R. Analyst 2014, 139, 2944. 4. Varki, A.; Sharon, N., Historical background and overview. 2009. 5. Fujita, M.; Kinoshita, T. Biochim. Biophys. Acta, Mol. Cell. Biol. Lipids 2012, 1821, 1050. 6. Iha, H.; Yamada, M. In T-Cell Leukemia-Characteristics, Treatment and Prevention, InTech: 2013. 7. Biswas, S.; Medina, S. H.; Barchi, J. J. Carbohydr. Res. 2015, 405, 93. 8. Siddiqui, M. A.; Ambre, S.; Keay, S. K.; Rhyne, J. M.; Zhang, C.-O.; Barchi Jr, J. J. ACS omega 2017, 2, 5618. 9. Kannagi, R.; Sakuma, K.; Cai, B.-H.; Yu, S.-Y. In Sugar Chains, Springer: 2015; pp 139-158. 10. Cazet, A.; Julien, S.; Bobowski, M.; Burchell, J.; Delannoy, P. Breast cancer Res. 2010, 12, 204. 11. Feng, D.; Shaikh, A. S.; Wang, F. ACS Chem. Biol. 2016, 11, 850. 12. Xu, Y.; Sette, A.; Sidney, J.; Gendler, S. J.; Franco, A. Immunol. Cell Biol 2005, 83, 440. 13. Heimburg-Molinaro, J.; Lum, M.; Vijay, G.; Jain, M.; Almogren, A.; Rittenhouse-Olson, K. Vaccine 2011, 29, 8802. 14. Brewer, C.; Haugstad, K.; Gerken, T.; Stokke, B.; Sletmoen, M. FASEB J. 2015, 29, 890. 15. Ferreira, J. A.; Videira, P. A.; Lima, L.; Pereira, S.; Silva, M.; Carrascal, M.; Severino, P. F.; Fernandes, E.; Almeida, A.; Costa, C. Mol. Oncol. 2013, 7, 719. 16. Li, Q.; Li, Z.; Duan, X.; Yi, W. J. Am. Chem. Soc. 2014, 136, 12536. 17. Li, F.; Glinskii, O. V.; Mooney, B. P.; Rittenhouse-Olson, K.; Pienta, K. J.; Glinsky, V. V. Oncotarget 2017, 8, 98598. 18. Westwood, J. A.; Murray, W. K.; Trivett, M.; Haynes, N. M.; Solomon, B.; Mileshkin, L.; Ball, D.; Michael, M.; Burman, A.; Mayura-Guru, P. J. Immunol. 2009, 32, 292. 19. Pochechueva, T.; Jacob, F.; Fedier, A.; Heinzelmann-Schwarz, V. Metabolites 2012, 2, 913. 20. Chang, W.-W.; Lee, C. H.; Lee, P.; Lin, J.; Hsu, C.-W.; Hung, J.-T.; Lin, J.-J.; Yu, J.-C.; Shao, L.-e.; Yu, J. Proc. Natl. Acad. Sci. 2008, 105, 11667. 21. Danishefsky, S. J.; Allen, J. R. Angew. Chem. Int. Ed. 2000, 39, 836. 22. Pifferi, C.; Berthet, N.; Renaudet, O. Biomaterials Science 2017, 5, 953. 23. Siegel, R. L.; Miller, K. D.; Jemal, A. CA: Cancer J. Clin. 2016, 66, 7. 24. Urruticoechea, A.; Alemany, R.; Balart, J.; Villanueva, A.; Vinals, F.; Capella, G. Curr. Pharm. Des. 2010, 16, 3. 25. Khalil, D. N.; Smith, E. L.; Brentjens, R. J.; Wolchok, J. D. Nat. Rev. Clin. Oncol. 2016, 13, 273. 26. Baeyens, J.-P. Expert Rev. vaccines 2010, 9, 11. 27. Slovin, S. F.; Keding, S. J.; Ragupathi, G. Immunol. Cell Biol. 2005, 83, 418. 28. Huang, Y.-L.; Hung, J.-T.; Cheung, S. K.; Lee, H.-Y.; Chu, K.-C.; Li, S.-T.; Lin, Y.-C.; Ren, C.-T.; Cheng, T.-J. R.; Hsu, T.-L. Proc. Natl. Acad. Sci. 2013, 110, 2517. 29. Gilewski, T. A.; Ragupathi, G.; Dickler, M.; Powell, S.; Bhuta, S.; Panageas, K.; Koganty, R. R.; Chin-Eng, J.; Hudis, C.; Norton, L. Clin. Cancer Res. 2007, 13, 2977. 30. Slovin, S. F.; Ragupathi, G.; Musselli, C.; Olkiewicz, K.; Verbel, D.; Kuduk, S. D.; Schwarz, J. B.; Sames, D.; Danishefsky, S.; Livingston, P. O. J. Clin. Oncol. 2003, 21, 4292. 31. Ragupathi, G.; Gardner, J. R.; Livingston, P. O.; Gin, D. Y. Expert Rev. vaccines 2011, 10, 463. 32. Sabbatini, P. J.; Kudryashov, V.; Ragupathi, G.; Danishefsky, S. J.; Livingston, P. O.; Bornmann, W.; Spassova, M.; Zatorski, A.; Spriggs, D.; Aghajanian, C. Int. J. Cancer 2000, 87, 79. 33. Dickler, M. N.; Ragupathi, G.; Liu, N. X.; Musselli, C.; Martino, D. J.; Miller, V. A.; Kris, M. G.; Brezicka, F.-T.; Livingston, P. O.; Grant, S. C. Clin. Cancer Res. 1999, 5, 2773. 34. Kirkwood, J. M.; Ibrahim, J. G.; Sosman, J. A.; Sondak, V. K.; Agarwala, S. S.; Ernstoff, M. S.; Rao, U. J. Clin. Oncol. 2001, 19, 2370. 35. O’Cearbhaill, R. E.; Ragupathi, G.; Zhu, J.; Wan, Q.; Mironov, S.; Yang, G.; Spassova, M. K.; Iasonos, A.; Kravetz, S.; Ouerfelli, O. Cancers 2016, 8, 46. 36. Astronomo, R. D.; Burton, D. R. Nat. Rev. Drug discovery 2010, 9, 308. 37. Mond, J. J.; Lees, A.; Snapper, C. M. Annu. Rev. Immunol. 1995, 13, 655. 38. Mond, J. J.; Vos, Q.; Lees, A.; Snapper, C. M. Curr. Opin. Immunol. 1995, 7, 349. 39. Ibrahim, N. K.; Murray, J. L. Clin. breast cancer 2003, 3, 139. 40. Eskola, J.; Käyhty, H.; Takala, A. K.; Peltola, H.; Rönnberg, P.-R.; Kela, E.; Pekkanen, E.; McVerry, P. H.; Mäkelä, P. H. N. Engl. J. Med. 1990, 323, 1381. 41. Avery, O. T.; Goebel, W. F. J. Exp. Med. 1931, 54, 437. 42. Helling, F.; Shang, A.; Calves, M.; Zhang, S.; Ren, S.; Robert, K. Y.; Oettgen, H. F.; Livingston, P. O. Cancer Res. 1994, 54, 197. 43. Wessels, M.; Paoletti, L.; Rodewald, A.; Michon, F.; DiFabio, J.; Jennings, H.; Kasper, D. Infect. immun. 1993, 61, 4760. 44. Plante, O. J.; Palmacci, E. R.; Seeberger, P. H. Science 2001, 291, 1523. 45. Zhang, Z.; Ollmann, I. R.; Ye, X.-S.; Wischnat, R.; Baasov, T.; Wong, C.-H. J. Am. Chem. Soc. 1999, 121, 734. 46. Ragupathi, G.; Koide, F.; Livingston, P. O.; Cho, Y. S.; Endo, A.; Wan, Q.; Spassova, M. K.; Keding, S. J.; Allen, J.; Ouerfelli, O. J. Am. Chem. Soc. 2006, 128, 2715. 47. Jones, C. An. Acad. Bras. Cienc. 2005, 77, 293. 48. Coffman, R. L.; Sher, A.; Seder, R. A. Immunity 2010, 33, 492. 49. Chapman, P. B.; Wu, D.; Ragupathi, G.; Lu, S.; Williams, L.; Hwu, W.-J.; Johnson, D.; Livingston, P. O. Clin. Cancer Res. 2004, 10, 4717. 50. Helling, F.; Zhang, S.; Shang, A.; Adluri, S.; Calves, M.; Koganty, R.; Longenecker, B. M.; Yao, T.-J.; Oettgen, H. F.; Livingston, P. O. Cancer Res. 1995, 55, 2783. 51. Gilewski, T.; Ragupathi, G.; Bhuta, S.; Williams, L. J.; Musselli, C.; Zhang, X.-F.; Bencsath, K. P.; Panageas, K. S.; Chin, J.; Hudis, C. A. Proc. Natl. Acad. Sci. 2001, 98, 3270. 52. Ragupathi, G.; Slovin, S. F.; Adluri, S.; Sames, D.; Kim, I. J.; Kim, H. M.; Spassova, M.; Bornmann, W. G.; Lloyd, K. O.; Scher, H. I. Angew. Chem. Int. Ed. 1999, 38, 563. 53. Lo-Man, R.; Vichier-Guerre, S.; Perraut, R.; Dériaud, E.; Huteau, V.; BenMohamed, L.; Diop, O. M.; Livingston, P. O.; Bay, S.; Leclerc, C. Cancer Res. 2004, 64, 4987. 54. Adluri, S.; Helling, F.; Ogata, S.; Zhang, S.; Itzkowitz, S. H.; Lloyd, K. O.; Livingston, P. O. Cancer Immunol. Immunother. 1995, 41, 185. 55. MacLean, G. D.; Reddish, M.; Koganty, R. R.; Wong, T.; Gandhi, S.; Smolenski, M.; Samuel, J.; Nabholtz, J. M.; Longenecker, B. M. Cancer Immunol. Immunother. 1993, 36, 215. 56. Huo, C.-X.; Zheng, X.-J.; Xiao, A.; Liu, C.-C.; Sun, S.; Lv, Z.; Ye, X.-S. Org. Biomol.Chem. 2015, 13, 3677. 57. Ragupathi, G.; Park, T. K.; Zhang, S.; Kim, I. J.; Graber, L.; Adluri, S.; Lloyd, K. O.; Danishefsky, S. J.; Livingston, P. O. Angew. Chem. Int. Ed. 1997, 36, 125. 58. Slovin, S.; Ragupathi, G.; Adluri, S.; Ungers, G.; Terry, K.; Kim, S.; Spassova, M.; Bornmann, W.; Fazzari, M.; Dantis, L. Proc. Natl. Acad. Sci. 1999, 96, 5710. 59. Zhu, J.; Warren, J. D.; Danishefsky, S. J. Expert Rev. vaccines 2009, 8, 1399. 60. Wilson, R. M.; Danishefsky, S. J. J. Am. Chem. Soc. 2013, 135, 14462. 61. Kuduk, S. D.; Schwarz, J. B.; Chen, X.-T.; Glunz, P. W.; Sames, D.; Ragupathi, G.; Livingston, P. O.; Danishefsky, S. J. J. Am. Chem. Soc. 1998, 120, 12474. 62. Zhang, S.; Zhang, H. S.; Cordon‐Cardo, C.; Reuter, V. E.; Singhal, A. K.; Lloyd, K. O.; Livingston, P. O. Int. J. Cancer 1997, 73, 50. 63. Ragupathi, G.; Cappello, S.; Canter, D.; Spassova, M.; Bornmann, W. G.; Danishefsky, S. J.; Livingston, P. O. Vaccine 2002, 20, 1030. 64. Ragupathi, G.; Koide, F.; Sathyan, N.; Kagan, E.; Spassova, M.; Bornmann, W.; Gregor, P.; Reis, C. A.; Clausen, H.; Danishefsky, S. J. Cancer Immunol. Immunother. 2003, 52, 608. 65. Keding, S. J.; Danishefsky, S. J. Proc. Natl. Acad. Sci. 2004, 101, 11937. 66. Allen, J. R.; Harris, C. R.; Danishefsky, S. J. J. Am. Chem. Soc. 2001, 123, 1890. 67. Ragupathi, G.; Coltart, D. M.; Williams, L. J.; Koide, F.; Kagan, E.; Allen, J.; Harris, C.; Glunz, P. W.; Livingston, P. O.; Danishefsky, S. J. Proc. Natl. Acad. Sci. 2002, 99, 13699. 68. Danishefsky, S. J.; Shue, Y.-K.; Chang, M. N.; Wong, C.-H. Acc. Chem. Res. 2015, 48, 643. 69. Livingston, P. O.; Wong, G.; Adluri, S.; Tao, Y.; Padavan, M.; Parente, R.; Hanlon, C.; Calves, M. J.; Helling, F.; Ritter, G. J. Clin. Oncol. 1994, 12, 1036. 70. Wang, S.-K.; Liang, P.-H.; Astronomo, R. D.; Hsu, T.-L.; Hsieh, S.-L.; Burton, D. R.; Wong, C.-H. Proc. Natl. Acad. Sci. 2008, 105, 3690. 71. Jeon, I.; Iyer, K.; Danishefsky, S. J. The Journal of organic chemistry 2009, 74, 8452. 72. Gilewski, T.; Adluri, S.; Ragupathi, G.; Zhang, S.; Yao, T.-J.; Panageas, K.; Moynahan, M.; Houghton, A.; Norton, L.; Livingston, P. O. Clin. Cancer Res. 2000, 6, 1693. 73. Chapman, P. B.; Morrissey, D.; Panageas, K.; Hamilton, W.; Zhan, C.; Destro, A.; Williams, L.; Israel, R.; Livingston, P. Clin. Cancer Res. 2000, 6, 874. 74. Carreño, L. J.; Kharkwal, S. S.; Porcelli, S. A. Immunotherapy 2014, 6, 309. 75. Anderson, R. J.; Li, J.; Kedzierski, L.; Compton, B. J.; Hayman, C. M.; Osmond, T. L.; Tang, C.-w.; Farrand, K. J.; Koay, H.-F.; Almeida, C. F. D. S. S. E. ACS Chem. Biol. 2017, 12, 2898. 76. Lou, Y.-W.; Wang, P.-Y.; Yeh, S.-C.; Chuang, P.-K.; Li, S.-T.; Wu, C.-Y.; Khoo, K.-H.; Hsiao, M.; Hsu, T.-L.; Wong, C.-H. Proc. Natl. Acad. Sci. 2014, 111, 2482. 77. Tsai, T.-I.; Lee, H.-Y.; Chang, S.-H.; Wang, C.-H.; Tu, Y.-C.; Lin, Y.-C.; Hwang, D.-R.; Wu, C.-Y.; Wong, C.-H. J. Am. Chem. Soc. 2013, 135, 14831. 78. Finn, A. Br. Med. Bull. 2004, 70, 1. 79. Bettahi, I.; Dasgupta, G.; Renaudet, O.; Chentoufi, A. A.; Zhang, X.; Carpenter, D.; Yoon, S.; Dumy, P.; BenMohamed, L. Cancer immunol. immunother. 2009, 58, 187. 80. Ingale, S.; Wolfert, M. A.; Gaekwad, J.; Buskas, T.; Boons, G.-J. Nat. Chem.Biol. 2007, 3, 663. 81. Mattson, G.; Conklin, E.; Desai, S.; Nielander, G.; Savage, M.; Morgensen, S. Mol. Biol. Rep. 1993, 17, 167. 82. Niemietz, M.; Perkams, L.; Hoffman, J.; Eller, S.; Unverzagt, C. Chem. Commun. 2011, 47, 10485. 83. Shimizu, Y.; Morimoto, H.; Zhang, M.; Ohshima, T. Angew. Chem. Int. Ed. 2012, 51, 8564. 84. Crestfield, A. M.; Moore, S.; Stein, W. H. J. Biol. Chem. 1963, 238, 622. 85. Konigsberg, W. Methods Enzymol. 1972, 25, 185. 86. Burns, J. A.; Butler, J. C.; Moran, J.; Whitesides, G. M. J. Org. Chem. 1991, 56, 2648. | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/69895 | - |
| dc.description.abstract | 大部分的癌症細胞表面會表現多量的特定醣抗原，先前研究顯示出Globo H, SSEA-4, SSEA-3等三種醣抗原會大量表現在至少16種不同類型的癌症細胞表面上而且在正常細胞中未被發現。此三種醣抗原之任一種在這16種癌症細胞中，出現的比例高達70%以上。因此，Globo H, SSEA-4, SSEA-3適合並有潛力做為抗癌疫苗之候選物。目前的臨床研究大多都是針對單一抗原所發展出來的疫苗，雖然本實驗室先前研發出的Globo H-DT疫苗可同時誘發針對Globo H, SSEA-3及SSEA-4此三種醣抗原之抗體，但其主要還是針對Globo H及SSEA-3的醣抗原。因此，在本篇研究中，我們想設計出一個多價的治療型抗癌疫苗，使其誘發出的抗體能夠對此三種醣抗原都具有高度的結合力，這種疫苗極有可能能夠同時對抗多種癌症。
此篇研究的目的在於將兩種或以上的醣抗原連接在一起，並將其接上載體蛋白以形成抗癌疫苗候選物。為了使不同的醣抗原能夠平均接在載體蛋白上，我們將Globo H和SSEA-4這兩種抗原接在一段短胜肽鍵上，使這兩種醣抗原的比例相同，最後和載體蛋白CRM-197(DT)接合，提升此多價抗癌疫苗的免疫性。藉由此合成策略，我們期望能設計出一組多價的抗癌疫苗，能夠有效率的治療不同的癌症。 | zh_TW |
| dc.description.abstract | Most cancer cell lines overexpress specific glycan antigens. Particularly, Globo H, SSEA-3, SSEA-4 of Globo series epitopes are found in at least 16 different types of cancer cell lines but not found in normal ones. The probability of finding one of the three Globo series epitopes in the 16 different types of cancer cell lines is up to 70%. Therefore, they are regarded as potential anticancer vaccine candidates. Most vaccine-associated studies were designed to elicit immune response to a single therapeutic target based on the uniqueness of each antigen. In 2013, our group published a Globo H-DT anticancer vaccine, which could simultaneously induce antibodies against Globo H, SSEA-4, and SSEA-3 antigens, but mostly against Globo H and SSEA-3. To have a universal anti-cancer vaccine, we designed a multivalent vaccine and hope it can induce immune response to all three specific glycan antigens with significantly binding. This multivalent anticancer vaccine can be used to simultaneously target different types of cancer.
In this study, we combined two glycan antigens and conjugated the combined antigens with carrier protein to form our target product. In order to evenly attach Globo H and SSEA-4 glycan antigens on the carrier protein, we connected Globo H and SSEA-4 with a short peptide to ensure equal proportions of both antigens. Finally, the glycopeptides were conjugated with the carrier protein CRM-197 (DT) to increase the immunity of this cancer vaccine candidate. We anticipate that this vaccine will be used for early stage treatment and even preventive application. | en |
| dc.description.provenance | Made available in DSpace on 2021-06-17T03:32:54Z (GMT). No. of bitstreams: 1 ntu-107-R04223216-1.pdf: 15452826 bytes, checksum: 07aa2c168e829300bc2d62ec1772ed29 (MD5) Previous issue date: 2018 | en |
| dc.description.tableofcontents | 中文摘要 ………………………………………………………………………….......i
ABSTRACT …………………………………………………………………………........ii ABBREVIATIONS …………………………………………….……………………….iii CONTENTS ………………………………………………………………………...….....v LIST OF FIGURES …………………………………………………………...………..vii LIST OF TABLES ……………………………………………………………...……..viii LIST OF SCHEMES ………………………………………………………….…...........ix Chapter 1 Introduction ………...……………………………………............…....1 1.1. Background …………………………………………………………………...1 1.2. Biological roles of carbohydrates ……………………………………...…..…1 1.3. Major classes of glycans ……………………………………………...………2 1.4. Tumor-associated carbohydrate antigens (TACAs) …………………………...3 1.5. Immunological response of carbohydrate antigens ……………………….......7 1.6. Carbohydrate-based anticancer vaccine development ………………...……...8 1.6.1. Challenges of carbohydrate-based anticancer vaccine development .....10 1.6.2. Development of monovalent vaccine ……………….….…….……......11 1.6.3. Development of multivalent vaccine …………………...……………...15 1.6.4. Development of Globo-H anticancer vaccine ………...…...………......19 1.7. Objection …………………………...……………………………………......21 Chapter 2 Result and discussion ………………………………………………..23 2.1. Chemoenzymatic synthesis of Globo H and SSEA-4 with sugar nucleotide regeneration ……………………………………………………………………………...23 2.2. Retro-synthesis of GH-DT-SSEA4 < 1st Generation > ………………………25 2.2.1. Retro-synthesis of GH-DT-SSEA4 < 2nd Generation > ………………28 2.2.2. Synthesis of modified SSEA3 (8) ……………………………..…......30 2.2.3. Strategies of detritylation …………......………………………...……33 2.2.4. Synthesis of modified GH (18) …………………………...………….34 2.2.5. Strategies of synthesis target compound 18 …………………….........37 2.3. Retro-synthesis of GH-DT-SSEA4 < 3rd Generation > ………………….......38 2.3.1. Synthesis of GH-DT-SSEA3 < 3rd Generation > ……………...…...…40 2.3.2. The possibility of the compound 35 formation …………………...….41 Chapter 3 Conclusion and Future perspective ...…………………………...….43 Chapter 4 Experiment section ……………………......…………………………45 4.1. General methods …………..……………………………………...………….45 4.2. Experiment section ………………………………………...…...……………46 References ………………………………………………………………………….…...65 APPENDIX (1H & 13C NMR) | |
| dc.language.iso | en | |
| dc.subject | 醣抗原 | zh_TW |
| dc.subject | Globo H | zh_TW |
| dc.subject | SSEA-4 | zh_TW |
| dc.subject | 癌症疫苗 | zh_TW |
| dc.subject | 異元二價 | zh_TW |
| dc.subject | Universal anticancer vaccine | en |
| dc.subject | glycan antigen | en |
| dc.subject | glycopeptide | en |
| dc.subject | SSEA-4 | en |
| dc.subject | Globo H | en |
| dc.title | 製備用於開發癌症疫苗之異元二價醣抗原 | zh_TW |
| dc.title | Preparation of a hetero-divalent glycan epitope for cancer vaccine development | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 106-1 | |
| dc.description.degree | 碩士 | |
| dc.contributor.oralexamcommittee | 吳宗益(Chung-Yi Wu),謝俊結(Jiun-Jie Shie) | |
| dc.subject.keyword | 醣抗原,Globo H,SSEA-4,癌症疫苗,異元二價, | zh_TW |
| dc.subject.keyword | Globo H,SSEA-4,Universal anticancer vaccine,glycan antigen,glycopeptide, | en |
| dc.relation.page | 99 | |
| dc.identifier.doi | 10.6342/NTU201800560 | |
| dc.rights.note | 有償授權 | |
| dc.date.accepted | 2018-02-13 | |
| dc.contributor.author-college | 理學院 | zh_TW |
| dc.contributor.author-dept | 化學研究所 | zh_TW |
| 顯示於系所單位： | 化學系 | |
文件中的檔案：
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| ntu-107-1.pdf 未授權公開取用 | 15.09 MB | Adobe PDF |
系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。